Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. (2022)

First Author: Gershenson DM
Attributed to:  Precision medicine and the mutational landscape of high grade serous ovarian cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)02175-9

PubMed Identifier: 35123694

Publication URI: http://europepmc.org/abstract/MED/35123694

Type: Journal Article/Review

Volume: 399

Parent Publication: Lancet (London, England)

Issue: 10324

ISSN: 0140-6736